A5101458787- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Monoclonal and Polyclonal Antibodies Research
- Systemic Sclerosis and Related Diseases
- T-cell and B-cell Immunology
- Neuroinflammation and Neurodegeneration Mechanisms
- Fungal Infections and Studies
- Bacterial Infections and Vaccines
- Cancer, Lipids, and Metabolism
- Urticaria and Related Conditions
- Glycosylation and Glycoproteins Research
- Autoimmune and Inflammatory Disorders Research
- Ichthyology and Marine Biology
- Medical and Biological Ozone Research
- Neurogenesis and neuroplasticity mechanisms
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Heart Rate Variability and Autonomic Control
- Skin and Cellular Biology Research
- Bone fractures and treatments
- Cardiovascular Health and Disease Prevention
- Immunodeficiency and Autoimmune Disorders
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiovascular Disease and Adiposity
- Hereditary Neurological Disorders
- Hip and Femur Fractures
Horizon Therapeutics (United States)
2021-2024
Amgen (United States)
2024
Horizon Therapeutics (United Kingdom)
2022-2023
National Cancer Center
2021
Hospices Civils de Lyon
2021
WinnMed
2021
University of California, San Francisco
2021
Observatoire Français de la Sclérose en Plaques
2021
Mayo Clinic in Arizona
2021
Mayo Clinic
2021
Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spectrum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial fibrillary acidic protein (sGFAP) concentration and NMOSD activity assessed of inebilizumab treatment.N-MOmentum was a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial adults with NMOSD. sGFAP levels were measured by single-molecule arrays...
Objective To investigate relationships between serum neurofilament light chain (sNfL), ubiquitin C-terminal hydrolase L1 (sUCHL1), tau (sTau) and glial fibrillary acidic protein (sGFAP) levels disease activity/disability in neuromyelitis optica spectrum disorder (NMOSD), the effects of inebilizumab on these biomarkers N-MOmentum. Methods N-MOmentum randomised participants to receive or placebo with a controlled period (RCP) 28 weeks an open-label follow-up ≥2 years. The sNfL, sUCHL1, sTau...
Inebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies. The relationship between B-cell, plasma-cell (PC), and immunoglobulin depletion longitudinal reductions NMOSD activity after inebilizumab was characterised post hoc exploratory analysis from N-MOmentum study (NCT02200770).Peripheral blood CD20+ B cells, PC gene signature, levels were assessed throughout (follow-up ≥2.5 years);...
<h3>Objective</h3> To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody, participants with neuromyelitis optica spectrum disorder (NMOSD). <h3>Methods</h3> Adults (N = 230) aquaporin-4 immunoglobulin G-seropositive NMOSD or -seronegative an EDSS ≤8 were randomized (3:1) to receive inebilizumab 300 mg placebo days 1 15. The controlled period...
The N-MOmentum trial, a double-blind, randomized, placebo-controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), enrolled participants who were aquaporin-4-immunoglobulin G (AQP4-IgG)-seropositive (AQP4+) or -seronegative (AQP4-). This article reports AQP4- participant outcomes.AQP4-IgG serostatus was determined for all screened by central laboratory, using validated, fluorescence-observation cell-binding assay. Medical histories and screening data...
Abstract Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B‐cells, is approved to treat aquaporin 4 (AQP4) IgG‐seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab afucosylated and engineered for enhanced affinity Fc receptor III‐A ( FCGR3A ) receptors on natural killer cells maximize antibody‐dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of gene (F158) was shown decrease IgG‐binding...
Background: The N-MOmentum trial investigated safety and efficacy of inebilizumab in participants with neuromyelitis optica spectrum disorder (NMOSD). Objective: Evaluate the attack identification process adjudication committee (AC) performance N-MOmentum. Methods: Adults ( n = 230) NMOSD Expanded Disability Status Scale score ⩽8 were randomized (3:1) to 300 mg or placebo. controlled period was 28 weeks until adjudicated attack. Attacks according 18 predefined criteria. Magnetic resonance...
A timeline of pediatric bone healing using fracture characteristics that can be assessed solely radiographs would practical for forensic casework, where the event may precede death by days, months, or years. However, dating fractures from is difficult, imprecise, and lacks consensus, as only a few aspects process are visible on radiographs. Multiple studies in both clinical literature have attempted to develop usable scale assess various characteristics. In contrast orthopedic definition,...
Monday, April 27April 14, 2020Free AccessSerum Neurofilament Light Chain Levels (sNfL) Correlate Best with Attack-related Disability in Neuromyelitis Optica (4105)O. Atkas, H-P. Hartung, M.A. Smith, W. Rees, K. Fujihara, F. Paul, R. Marignier, … Show All , J.L. Bennett, H.J. Kim, B. Weinshenker, S.J. Pittock, D. Wingerchuk, G. Cutter, A. Green, Mealy, J. Drappa, Barron, S. Madani, L. Wang, She, Cimbora, J.N. Ratchford, E. Katz, and B.A.C Cree FewerAuthors Info & AffiliationsApril 2020...
Recent reports have indicated that resistance exercise training performed absent an aerobic program may increase arterial stiffness. Our purpose was to compare the augmentation index (AIx) and left ventricular wasted pressure energy (LVEW) as markers of stiffness ventricular‐vascular coupling efficiency in young (AT) (RT) trained athletes. We also investigated relationship between muscle sympathetic nerve activity (MSNA) AIx determine if outflow could explain any observed differences...
Conference Article| December 01 1989 Phospholipids are visible in 31P n.m.r. spectra of human breast tumours MARTIN LOWRY; LOWRY *I.C.R.F. Clinical Oncology Unit and Division Radiological Sciences, Guy's Hospital, London SE1 9RT, U.K. Search for other works by this author on: This Site PubMed Google Scholar DAVID A. PORTER; PORTER †Division CHRISTOPHER J. TWELVES; TWELVES PHILIPPA E. HEASLEY; HEASLEY PAMELA B. GARLICK; GARLICK MICHAEL SMITH; SMITH ROBERT D. RUBENS; RUBENS N. MAISEY; MAISEY...